Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

  • April 2020 •
  • 15 pages •
  • Report ID: 5903915 •
  • Format: PDF
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.